[Oracle and AstraZeneca collaborate to explore AI medical applications] On October 20, Oracle and AstraZeneca announced a non-binding agreement to explore the use of artificial intelligence (AI) and real-world data to identify patients eligible for clinical trials, accelerate the generation of medical evidence, and integrate relevant research results into daily diagnosis and treatment processes. The two parties will combine AstraZeneca's scientific research and therapeutic expertise with Oracle's data, cloud computing, AI and clinical workflow technologies. The two parties are initially considering exploring applications in the fields of tumors, cardiovascular, renal and metabolic diseases, respiratory and immune diseases, and rare diseases, and plan to establish a joint governance mechanism and effect evaluation indicators to evaluate whether relevant solutions can be extended to more disease areas.